ACVRL1 Protein (His tag)

Produktnummer ABIN2566280

Produktdetails

Target: ACVRL1 (Activin A Receptor Type II-Like 1 (ACVRL1))

Protein-Typ: Recombinant

Biologische Aktivität: Active

Spezies: Human

Quelle: HEK-293 Cells

Aufreinigungstag / Konjugat: Dieses ACVRL1 Protein ist gelabelt mit His tag.

Applikation: Western Blotting (WB)

Produktmerkmale:

Measured by its ability to inhibit BMP9 induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED50 for this effect is typically 1-3 ng/mL in the presence of 2 ng/mL of rhBMP9.

Reinheit: >97 % as determined by SDS-PAGE.

Anwendungsinformationen

Applikationshinweise: This recombinant protein can be used for WB. For research use only.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: PBS, pH 7.4

Lagerung: -80 °C,-20 °C

Informationen zur Lagerung: Lyophilized Protein should be stored at -20°C or lower for long term storage. Upon reconstitution, working aliquots should be stored at -20°C or -70°C. Avoid repeated freeze-thaw cycles.

Antigendetails

Target: ACVRL1 (Activin A Receptor Type II-Like 1 (ACVRL1))

Andere Bezeichnung: ALK 1 (ACVRL1 Produkte)

Synonyme: ACVRL1 Protein, vgb Protein, alk1 Protein, zehn1109 Protein, hm:zehn1109 Protein, ACVRLK1 Protein, ALK-1 Protein, ALK1 Protein, HHT Protein, HHT2 Protein, ORW2 Protein, SKR3 Protein, TSR-I Protein, R-3 Protein, R3 Protein, SETHKIR Protein, AI115505 Protein, AI427544 Protein, Acvrlk1 Protein, Alk1 Protein, activin A receptor like type 1 Protein, activin A receptor type II-like 1 Protein, activin A receptor, type II-like 1 Protein, ACVRL1 Protein, acvrl1 Protein, Acvrl1 Protein

Hintergrund: Serine/threonine-protein kinase receptor R3 is an enzyme that in humans is encoded by the ALK1 gene. ALK1 is a receptor in the TGF beta signaling pathway. ALK1 protein is a receptor in the TGF beta signaling pathway. It plays an important role in vascular development, remodeling, and pathologic angiogenesis, play a role in stabilizing angiogenic vessels and contribute to resistance to anti-VEGF therapies, ALK1 blockade may represent an effective therapeutic opportunity complementary to the current antiangiogenic modalities in the clinic. Recently, researcher found that, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate, in a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor-, fibroblast growth factor-, and BMP10-mediated vessel formation, and ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells.

Molekulargewicht: 12.3 kDa

Gen-ID: 94

NCBI Accession: NP_000011

UniProt: P37023